SG11201509265SA - Avoiding narcolepsy risk in influenza vaccines - Google Patents

Avoiding narcolepsy risk in influenza vaccines

Info

Publication number
SG11201509265SA
SG11201509265SA SG11201509265SA SG11201509265SA SG11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA
Authority
SG
Singapore
Prior art keywords
narcolepsy
avoiding
risk
influenza vaccines
influenza
Prior art date
Application number
SG11201509265SA
Inventor
Syed Sohail Ahmed
Lawrence Steinman
Wayne Volkmuth
Original Assignee
Novartis Ag
Lawrence Steinman
Wayne Volkmuth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Lawrence Steinman, Wayne Volkmuth filed Critical Novartis Ag
Publication of SG11201509265SA publication Critical patent/SG11201509265SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
SG11201509265SA 2013-05-10 2014-05-12 Avoiding narcolepsy risk in influenza vaccines SG11201509265SA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361822228P 2013-05-10 2013-05-10
US201361859113P 2013-07-26 2013-07-26
US201361862807P 2013-08-06 2013-08-06
EP13181429 2013-08-23
EP14158999 2014-03-11
PCT/EP2014/059672 WO2014180999A1 (en) 2013-05-10 2014-05-12 Avoiding narcolepsy risk in influenza vaccines

Publications (1)

Publication Number Publication Date
SG11201509265SA true SG11201509265SA (en) 2015-12-30

Family

ID=51660716

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509265SA SG11201509265SA (en) 2013-05-10 2014-05-12 Avoiding narcolepsy risk in influenza vaccines

Country Status (11)

Country Link
US (3) US20140335116A1 (en)
EP (1) EP2801372A3 (en)
JP (1) JP2016521282A (en)
KR (1) KR20160030097A (en)
CN (1) CN105828835A (en)
AU (1) AU2014264501A1 (en)
BR (1) BR112015028314A2 (en)
CA (1) CA2911296A1 (en)
MX (1) MX2015015428A (en)
SG (1) SG11201509265SA (en)
WO (1) WO2014180999A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801372A3 (en) 2013-05-10 2015-02-18 Novartis AG Avoiding narcolepsy risk in influenza vaccines
WO2017140845A1 (en) * 2016-02-18 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor
WO2019140305A1 (en) * 2018-01-12 2019-07-18 The Regents Of The University Of California Spectroscopic biological material characterization
CN111803625B (en) * 2020-09-09 2020-12-18 天津中逸安健生物科技有限公司 Subunit influenza vaccine cracking agent and application thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (en) 1983-01-25 1991-10-31 Ciba Geigy Ag NEW PEPTIDE DERIVATIVES.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (en) 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
DE19612966B4 (en) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK cells and methods of propagating influenza viruses
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
TR200200776T2 (en) 1999-09-24 2002-06-21 Smithkline Beecham Biologicals S.A. Intranasal flu virus vaccine.
AU2001236042B9 (en) 2000-03-03 2006-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
WO2002074336A2 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7273852B2 (en) 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
KR20090051129A (en) 2004-04-05 2009-05-20 화이자 프로덕츠 인코포레이티드 Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
WO2005113758A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
US20090081253A1 (en) * 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
GB0506001D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Novel use
FR2884255B1 (en) 2005-04-11 2010-11-05 Vivalis USE OF EBX AVIATION STEM CELL LINES FOR THE PRODUCTION OF INFLUENZA VACCINE
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
TWI382019B (en) 2005-08-19 2013-01-11 Array Biopharma Inc Aminodiazepines as toll-like receptor modulators
CN101365480B (en) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
EA014028B1 (en) * 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa EMULSION OIL IN THERMOREVERSIBLE WATER
PT2038290E (en) 2006-07-07 2013-12-10 Gilead Sciences Inc Modulators of toll-like receptor 7
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2397714T3 (en) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil-in-water emulsion adjuvant
WO2008047174A1 (en) 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
US9073913B2 (en) 2008-03-24 2015-07-07 4Sc Ag Substituted imidazoquinolines
EP2313111B1 (en) 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
CN102257135B (en) * 2008-12-16 2017-06-09 纳米医疗公司 The production of influenza vaccines
NZ596671A (en) * 2009-05-29 2013-06-28 Novartis Ag Assays for influenza virus hemagglutinins
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
EA023725B1 (en) 2010-03-23 2016-07-29 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
CN105999275A (en) 2010-09-01 2016-10-12 诺华有限公司 Adsorption of immunopotentiators to insoluble metal salts
EP2801372A3 (en) 2013-05-10 2015-02-18 Novartis AG Avoiding narcolepsy risk in influenza vaccines

Also Published As

Publication number Publication date
CA2911296A1 (en) 2014-11-13
BR112015028314A2 (en) 2017-09-19
US20170216425A1 (en) 2017-08-03
WO2014180999A1 (en) 2014-11-13
EP2801372A2 (en) 2014-11-12
US20190184007A1 (en) 2019-06-20
EP2801372A3 (en) 2015-02-18
CN105828835A (en) 2016-08-03
US20140335116A1 (en) 2014-11-13
AU2014264501A1 (en) 2015-12-10
MX2015015428A (en) 2016-07-18
KR20160030097A (en) 2016-03-16
JP2016521282A (en) 2016-07-21

Similar Documents

Publication Publication Date Title
IL276210A (en) Mers-cov vaccine
IL279395A (en) Vaccine composition
HK1226440A1 (en) Cmv vaccines
HK1207967A1 (en) Vaccine
HK1211224A1 (en) Multivalent glycoconjugate vaccines
ZA201508642B (en) Malaria vaccine
GB201318084D0 (en) Malaria vaccination
GB201315946D0 (en) Oncology vaccine
EP2876161A4 (en) Vaccine
GB201223386D0 (en) Vaccine
GB201301085D0 (en) Glycoconjugate Vaccine
ZA201409124B (en) Reassortant btv and ahsv vaccines
EP3022298A4 (en) Attenuated influenza vaccines and uses thereof
HK1217206A1 (en) Vaccine
SG11201509265SA (en) Avoiding narcolepsy risk in influenza vaccines
AP2015008615A0 (en) Vaccines against pregnancy-associated malaria
GB201301119D0 (en) Viral vaccines
ZA201508215B (en) Avoiding narcolepsy risk in influenza vaccines
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
AP2014000880S (en) Fan
GB201217321D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201206169D0 (en) Vaccine